OBJECTIVE: Posttraumatic stress disorder (PTSD) increases cardiovascular disease and cardiovascular mortality risk. Neither the prospective relationship of PTSD to incident hypertension risk nor the effect of PTSD treatment on hypertension risk has been established. METHODS: Data from a nationally representative sample of 194,319 veterans were drawn from the Veterans Administration (VA) roster of United States service men and women. This included veterans whose end of last deployment was from September 2001 to July 2010 and whose first VA medical visit was from October 1, 2001 to January 1, 2009. Incident hypertension was modeled as 3 events: (1) a new diagnosis of hypertension and/or (2) a new prescription for antihypertensive medication, and/or (3) a clinic blood pressure reading in the hypertensive range (≥140/90 mm Hg, systolic/diastolic). Posttraumatic stress disorder diagnosis was the main predictor. Posttraumatic stress disorder treatment was defined as (1) at least 8 individual psychotherapy sessions of 50 minutes or longer during any consecutive 6 months and/or (2) a prescription for selective serotonin reuptake inhibitor medication. RESULTS: Over a median 2.4-year follow-up, the incident hypertension risk independently associated with PTSD ranged from hazard ratio (HR), 1.12 (95% confidence interval [CI], 1.08-1.17; p < .0001) to HR, 1.30 (95% CI, 1.26-1.34; p < .0001). The interaction of PTSD and treatment revealed that treatment reduced the PTSD-associated hypertension risk (e.g., from HR, 1.44 [95% CI, 1.38-1.50; p < .0001] for those untreated, to HR, 1.20 [95% CI, 1.15-1.25; p < .0001] for those treated). CONCLUSIONS: These results indicate that reducing the long-term health impact of PTSD and the associated costs may require very early surveillance and treatment.
OBJECTIVE:Posttraumatic stress disorder (PTSD) increases cardiovascular disease and cardiovascular mortality risk. Neither the prospective relationship of PTSD to incident hypertension risk nor the effect of PTSD treatment on hypertension risk has been established. METHODS: Data from a nationally representative sample of 194,319 veterans were drawn from the Veterans Administration (VA) roster of United States service men and women. This included veterans whose end of last deployment was from September 2001 to July 2010 and whose first VA medical visit was from October 1, 2001 to January 1, 2009. Incident hypertension was modeled as 3 events: (1) a new diagnosis of hypertension and/or (2) a new prescription for antihypertensive medication, and/or (3) a clinic blood pressure reading in the hypertensive range (≥140/90 mm Hg, systolic/diastolic). Posttraumatic stress disorder diagnosis was the main predictor. Posttraumatic stress disorder treatment was defined as (1) at least 8 individual psychotherapy sessions of 50 minutes or longer during any consecutive 6 months and/or (2) a prescription for selective serotonin reuptake inhibitor medication. RESULTS: Over a median 2.4-year follow-up, the incident hypertension risk independently associated with PTSD ranged from hazard ratio (HR), 1.12 (95% confidence interval [CI], 1.08-1.17; p < .0001) to HR, 1.30 (95% CI, 1.26-1.34; p < .0001). The interaction of PTSD and treatment revealed that treatment reduced the PTSD-associated hypertension risk (e.g., from HR, 1.44 [95% CI, 1.38-1.50; p < .0001] for those untreated, to HR, 1.20 [95% CI, 1.15-1.25; p < .0001] for those treated). CONCLUSIONS: These results indicate that reducing the long-term health impact of PTSD and the associated costs may require very early surveillance and treatment.
Authors: Robert B Schonberger; Matthew M Burg; Natalie Holt; Carrie L Lukens; Feng Dai; Cynthia Brandt Journal: Anesth Analg Date: 2011-11-10 Impact factor: 5.108
Authors: Michelle E Costanzo; Suzanne Leaman; Tanja Jovanovic; Seth D Norrholm; Albert A Rizzo; Patricia Taylor; Michael J Roy Journal: Psychosom Med Date: 2014 Nov-Dec Impact factor: 4.312
Authors: Marian Abouzeid; Helen L Kelsall; Andrew B Forbes; Malcolm R Sim; Mark C Creamer Journal: J Psychosom Res Date: 2011-09-21 Impact factor: 3.006
Authors: Joseph L Goulet; Shawn L Fultz; David Rimland; Adeel Butt; Cynthia Gibert; Maria Rodriguez-Barradas; Kendall Bryant; Amy C Justice Journal: Clin Infect Dis Date: 2007-12-15 Impact factor: 9.079
Authors: Jeffrey F Scherrer; Joanne Salas; F David Schneider; Matthew J Friedman; Carissa van den Berk-Clark; Kathleen M Chard; Sonya B Norman; Patrick J Lustman; Peter Tuerk; Paula P Schnurr; Beth E Cohen Journal: J Psychosom Res Date: 2020-05-04 Impact factor: 3.006
Authors: Stacey Kaltman; Maria Rosa Watson; Marcela Campoli; Adriana Serrano; Nicholas Talisman; Laura Kirkpatrick; Mihriye Mete; Bonnie L Green Journal: Cultur Divers Ethnic Minor Psychol Date: 2019-02-28
Authors: Pedro L Valenzuela; Pedro Carrera-Bastos; Beatriz G Gálvez; Gema Ruiz-Hurtado; José M Ordovas; Luis M Ruilope; Alejandro Lucia Journal: Nat Rev Cardiol Date: 2020-10-09 Impact factor: 32.419
Authors: Casey E Cavanagh; Lindsey Rosman; Philip W Chui; Lori Bastian; Cynthia Brandt; Sally Haskell; Matthew M Burg Journal: Health Psychol Date: 2020-01-30 Impact factor: 4.267
Authors: Allison E Gaffey; Nancy S Redeker; Lindsey Rosman; Janet M Mullington; Cynthia A Brandt; Sally G Haskell; Matthew M Burg Journal: J Hypertens Date: 2020-04 Impact factor: 4.844
Authors: Jeffrey F Scherrer; Joanne Salas; Matthew J Friedman; Beth E Cohen; F David Schneider; Patrick J Lustman; Carissa van den Berk-Clark; Kathleen M Chard; Peter Tuerk; Sonya B Norman; Paula P Schnurr Journal: Health Psychol Date: 2020-03-30 Impact factor: 4.267
Authors: Ida T Fonkoue; Paul J Marvar; Seth Norrholm; Yunxiao Li; Melanie L Kankam; Toure N Jones; Monica Vemulapalli; Barbara Rothbaum; J Douglas Bremner; Ngoc-Anh Le; Jeanie Park Journal: Brain Behav Immun Date: 2019-11-01 Impact factor: 7.217
Authors: Jennifer A Sumner; Adam X Maihofer; Vasiliki Michopoulos; Alex O Rothbaum; Lynn M Almli; Ole A Andreassen; Allison E Ashley-Koch; Dewleen G Baker; Jean C Beckham; Bekh Bradley; Gerome Breen; Jonathan R I Coleman; Anders M Dale; Michelle F Dennis; Norah C Feeny; Carol E Franz; Melanie E Garrett; Charles F Gillespie; Guia Guffanti; Michael A Hauser; Sian M J Hemmings; Tanja Jovanovic; Nathan A Kimbrel; William S Kremen; Bruce R Lawford; Mark W Logue; Adriana Lori; Michael J Lyons; Jessica Maples-Keller; Matig R Mavissakalian; Regina E McGlinchey; Divya Mehta; Rebecca Mellor; William Milberg; Mark W Miller; Charles Phillip Morris; Matthew S Panizzon; Kerry J Ressler; Victoria B Risbrough; Barbara O Rothbaum; Peter Roy-Byrne; Soraya Seedat; Alicia K Smith; Jennifer S Stevens; Leigh Luella van den Heuvel; Joanne Voisey; Ross McD Young; Lori A Zoellner; Caroline M Nievergelt; Erika J Wolf Journal: Front Neurosci Date: 2021-06-23 Impact factor: 4.677